AMPD2

AMP deaminase 2 · Q01433 · AMPD2 on Sugi Atlas →

1,913 patent compounds predicted against AMPD2, 391 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL23124104 SCHEMBL23124104 0.51 15/20
SCHEMBL29789663 SCHEMBL29789663 0.51 15/20
SCHEMBL13503917 SCHEMBL13503917 0.52 14/20
SCHEMBL27979486 SCHEMBL27979486 0.51 12/20
SCHEMBL13681455 SCHEMBL13681455 0.52 11/20
SCHEMBL23123725 SCHEMBL23123725 0.52 11/20
SCHEMBL29790009 SCHEMBL29790009 0.52 11/20
SCHEMBL20915109 SCHEMBL20915109 0.57 10/20
SCHEMBL15718613 SCHEMBL15718613 0.54 9/20
SCHEMBL13415334 SCHEMBL13415334 0.51 9/20
SCHEMBL11007123 SCHEMBL11007123 0.44 9/20
SCHEMBL26932396 SCHEMBL26932396 0.51 8/20
SCHEMBL31599737 SCHEMBL31599737 0.44 8/20
SCHEMBL31415088 SCHEMBL31415088 0.52 7/20
SCHEMBL11784247 SCHEMBL11784247 0.50 7/20
SCHEMBL28577145 SCHEMBL28577145 0.45 7/20
SCHEMBL11668979 SCHEMBL11668979 0.45 7/20
SCHEMBL11008168 SCHEMBL11008168 0.41 7/20
Coformycin Coformycin (SCHEMBL11184406) 0.51 6/20
Coformycin Coformycin (SCHEMBL14031897) 0.51 6/20

Clinical trials — most relevant to AMPD2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Genomic Outcomes of Metformin PHASE4COMPLETED
Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer PHASE4WITHDRAWN
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
Acelarin First Line Randomised Pancreatic Study PHASE2/PHASE3SUSPENDED
Vitamin D Status in Patients With Severe Sepsis PHASE3WITHDRAWN
The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY) PHASE2/PHASE3COMPLETED
MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID PHASE2COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia PHASE2COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial) PHASE2RECRUITING
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals PHASE1/PHASE2COMPLETED
University of California, San Diego (UCSD) Suramin Autism Treatment-1 (SAT1) Trial PHASE1/PHASE2COMPLETED
Pentoxifylline as an Adjunctive in Treatment of Negative Symptoms in Chronic Schizophrenia PHASE1/PHASE2COMPLETED
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer PHASE1COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism. PHASE1COMPLETED
A Phase I Trial of SHR3162 in Subjects With Advanced Solid Tumors PHASE1COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Effects of Pimecrolimus on Skin Biopsy Ex-plants From Patients With Atopic Dermatitis nanCOMPLETED
Effect of Polymorphisms in the Adenosine a2a Receptor Gene and AMPD2 Gene on Adenosine-Induced Vasodilation and Reactive Hyperemia nanCOMPLETED
Evaluation of Adenosine Deaminase (ADA) Enzyme Deficiency in Patients With Lymphopenia and/or Elevated Immunoglobulin E nanUNKNOWN
ADAR1 Expression Level in Rectal Cancer nanRECRUITING
Epigenetics, DNA Methylation Patterns and Periodontal Disease nanCOMPLETED
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA) nanUNKNOWN
Prevalence of Adenosine Deaminase (ADA) Enzyme Deficiency Disease in Adult Patients With Pulmonary Alveolar Proteinosis nanUNKNOWN
Role and Interactions of Adenosine, Receptors, Methionine Cycle Nutritional, Metabolic and Genetic Determinants in the Onset of Atrial Fibrillation in Normal Heart nanUNKNOWN
Study of Selected X-Linked Disorders: Aicardi Syndrome nanRECRUITING
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis nanNOT_YET_RECRUITING
Leveraging Artificial Intelligence and Multi-Omics Data to Predict Opioid Addiction nanACTIVE_NOT_RECRUITING
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages nanCOMPLETED
Genetic Characterization of Parkinson's Disease nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a AMPD2 binder may also engage these)

ProteinNameSimilarity
Q9DBT5 1.000 Q9DBT5 →
Q02356 1.000 Q02356 →
O08739 0.999 O08739 →
O09178 0.996 O09178 →
P10759 0.993 P10759 →
AMPD3 AMP deaminase 3 0.992 landscape →
AMPD1 AMP deaminase 1 0.991 landscape →
A7Z050 0.991 A7Z050 →
Q6PFW1 0.989 Q6PFW1 →
Q3V1D3 0.987 Q3V1D3 →
P0C644 0.987 P0C644 →
Q5XHF8 0.986 Q5XHF8 →
F4J8C6 0.986 F4J8C6 →
P54310 0.986 P54310 →
Q5RDF1 0.986 Q5RDF1 →
O00562 0.985 O00562 →
Q9Z0S8 0.985 Q9Z0S8 →
O80452 0.985 O80452 →
Q68J42 0.984 Q68J42 →
Q84WW3 0.984 Q84WW3 →
P50998 0.984 P50998 →
A2ARP1 0.984 A2ARP1 →
Q499S9 0.984 Q499S9 →
Q58CP9 0.984 Q58CP9 →
A9L8T6 0.984 A9L8T6 →
O35954 0.984 O35954 →
Q6GMF8 0.984 Q6GMF8 →
Q84NP7 0.984 Q84NP7 →
Q6PIX5 0.983 Q6PIX5 →
Q6ZQB6 0.983 Q6ZQB6 →